Overview

Alvimopan as a Rescue Treatment of Postoperative Ileus

Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
0
Participant gender:
All
Summary
This study aims to evaluate the cost effectiveness of Alvimopan as rescue therapy in patients undergoing colorectal or small bowel resection who develop POI, and its safety and effectiveness in reducing LOS and POI duration. This will be a prospective randomized control trial with a total of 58 patients, 29 in each group. Patients who undergo laparoscopic or open colorectal resection, small bowel resection, or ileostomy reversal with small bowel resection that subsequently develop postoperative ileus will be eligible for enrollment. If they meet inclusion/exclusion criteria, they will be randomized at the time of diagnosis of postoperative ileus to receive Alvimopan as rescue therapy or to receive conservative standard care. Patients randomized to the study group will be given a maximum of 3 doses of Alvimopan 12mg orally, 12 hours apart. Alvimopan will be given from the time of diagnosis of postoperative ileus to the time of return of bowel function or the maximum 3 doses. Subsequent Alvimopan doses will be given if there is no return of bowel function or if symptoms of distension and/or nausea persist despite some return of bowel function.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Scott Steele
The Cleveland Clinic
Treatments:
Alvimopan
Criteria
Inclusion Criteria:

- 1. Subjects who have benign or malignant colonic or rectal disease that have undergone
laparoscopic or open colorectal resection, small bowel resection or ileostomy reversal
with small bowel resection and subsequently developed postoperative ileus, defined as:

a. Patients with symptoms of bloating with or without nausea and vomiting, with
absence of passage of flatus or stool who require either

i. Return to NPO status after initial diet attempts

ii. Undergo placement of a nasogastric tube

b. Patients with absence of passage of flatus or stool who are either

i. More than 5 days after open surgery without recovery of GI function

ii. More than 3 days after laparoscopic surgery or ileostomy closure without recovery of GI
function

2. Subjects who are 18 years of age and older

3. Subjects of either gender

4. Subjects who are willing and able to adhere to protocol requirements, agree to
participate in the study program and provide written and informed consent.

Exclusion Criteria:

- 1. Subjects who received Alvimopan preoperatively.

2. Subjects that have taken therapeutic doses of opioids for more than 7 days
immediately prior to surgery.

3. Subjects with severe hepatic impairment.

4. Subjects with end-stage renal disease.

5. Subjects who are pregnant.

6. Subjects who have undergone imaging suggesting a small bowel obstruction.

7. Subjects with a medical condition that may interfere with the use of the study
medication Alvimopan.

8. Subjects who have a condition or general disability or infirmity that in the
opinion of the investigator precludes further participation in the study